GlassScriptPhysician profile
Ronald Willoughby
NPI 1477582823
$936.10
in general payments reported to CMS, 2019-2025
18 companies · $242 in 2025
The $242 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.26 · 2021: $41.09 · 2022: $45.77 · 2023: $330 · 2024: $214 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $785.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $208.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $123.25 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $117.33 | 2021-2023 | Ubrelvy |
| Lilly USA, LLC | $95.85 | 2022-2025 | Mounjaro, Emgality, Jardiance |
| Astrazeneca Pharmaceuticals LP | $94.76 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $59.24 | 2019-2025 | |
| Idorsia Pharmaceuticals US INC | $32.41 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $32.03 | 2025 | |
| Glaxosmithkline, LLC. | $31.74 | 2024 | Shingrix, Arexvy |
| Abbott Laboratories | $23.94 | 2023 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.74 | 2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.00 | 2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $16.42 | 2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $15.23 | 2023 | Eliquis |
| Amgen INC. | $15.00 | 2024 | Otezla, Repatha |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $13.79 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $11.15 | 2019 | |
| Sanofi Pasteur INC. | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Willoughby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.